Bio Clinical Biostatistics Adaptive Designs

Designs adaptive clinical trials including group-sequential (O'Brien-Fleming, Pocock, Lan-DeMets spending), sample-size re-estimation (blinded Friede-Kieser, unblinded Cui-Hung-Wang, Mehta-Pocock promising zone), seamless Phase 2/3 with treatment-arm selection, population enrichment, and response-adaptive randomisation. Covers FDA 2019 Final Adaptive Designs Guidance, FDA 2022 Master Protocols, and ICH E20 Step 2b/3 draft (June 2025, NOT final). Use when planning interim analyses, sample-size re-estimation, or master/platform-trial designs.

pku-yuangroup Updated 665 repo stars
OpenAI4S · Open AI for Scientist

File contents

pku-yuangroup/openai4s commit b4d56e121e

Frequently asked questions

npx get-skill add pku-yuangroup/bio-clinical-biostatistics-adaptive-designs